Point72 Europe London LLP Purchases New Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Point72 Europe London LLP acquired a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 68,202 shares of the medical equipment provider’s stock, valued at approximately $7,402,000.

Other hedge funds have also recently bought and sold shares of the company. OLD Point Trust & Financial Services N A bought a new position in Zimmer Biomet in the fourth quarter valued at about $26,000. Crewe Advisors LLC bought a new position in shares of Zimmer Biomet in the 1st quarter valued at about $31,000. Ables Iannone Moore & Associates Inc. acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $30,000. J.Safra Asset Management Corp grew its position in shares of Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 235 shares during the period. Finally, Family Firm Inc. bought a new stake in shares of Zimmer Biomet during the second quarter worth approximately $33,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 0.3 %

Zimmer Biomet stock opened at $107.85 on Wednesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $133.90. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The company has a 50 day moving average of $109.86 and a 200-day moving average of $115.11. The stock has a market capitalization of $21.96 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 1.97 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period in the prior year, the business earned $1.82 EPS. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.01 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZBH. TD Cowen reduced their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, September 17th. Barclays dropped their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a report on Friday, May 31st. Raymond James reduced their target price on Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. decreased their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.